Latest Period
Q4 2025
Security Snapshot
Kezar Life Sciences, Inc. - Common Stock (KZR) Institutional Ownership
CUSIP: 49372L209
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
43
Shares (Excl. Options)
4,460,455
Price
$6.29
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- KZR on Nasdaq
- Shares outstanding
- 7,437,095
- Price per share
- $7.42
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 4,460,455
- Total reported value
- $28,054,562
- % of total 13F portfolios
- 0%
- Share change
- +278,709
- Value change
- +$2,498,477
- Number of holders
- 43
- Price from insider filings
- $7.42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- KZR - Kezar Life Sciences, Inc. - Common Stock is tracked under CUSIP 49372L209.
- 43 institutions reported positions in Q4 2025.
- 1 significant owner is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 43 to 9 between Q4 2025 and Q1 2026.
- Reported value moved from $28,054,562 to $9,966,057.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 43 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 49372L209?
CUSIP 49372L209 identifies KZR - Kezar Life Sciences, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 49372L209:
Significant Owners of Kezar Life Sciences, Inc. - Common Stock (KZR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 2.1% | -62% | $968,310 | -$1,370,578 | 156,179 | -59% | Stonepine Capital Management, LLC | 31 Dec 2025 |
As of 31 Dec 2025, 43 institutional investors reported holding 4,460,455 shares of Kezar Life Sciences, Inc. - Common Stock (KZR). This represents 60% of the company’s total 7,437,095 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Kezar Life Sciences, Inc. - Common Stock (KZR) together control 59% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 9.7% | 720,787 | 0% | 4% | $4,533,750 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.6% | 716,759 | 0% | 0.11% | $4,508,414 |
| TANG CAPITAL MANAGEMENT LLC | 8.9% | 664,314 | -7.7% | 0.21% | $4,178,535 |
| VANGUARD GROUP INC | 4.6% | 341,404 | +27% | 0% | $2,147,431 |
| Nantahala Capital Management, LLC | 3.7% | 276,754 | 0.1% | $1,740,783 | |
| Affinity Asset Advisors, LLC | 3.1% | 229,076 | 0.1% | $1,440,888 | |
| Stonepine Capital Management, LLC | 2.1% | 156,179 | -59% | 0.78% | $982,366 |
| RENAISSANCE TECHNOLOGIES LLC | 1.8% | 131,285 | +13% | 0% | $825,783 |
| Peapod Lane Capital LLC | 1.7% | 126,699 | +0.74% | 0.68% | $796,937 |
| ACADIAN ASSET MANAGEMENT LLC | 1.7% | 125,371 | -6.1% | 0% | $787,000 |
| ADAR1 Capital Management, LLC | 1.6% | 117,440 | -6% | 0.06% | $738,698 |
| Ikarian Capital, LLC | 1.4% | 102,211 | -4.4% | 0.08% | $642,907 |
| BlackRock, Inc. | 1.3% | 98,684 | +0.59% | 0% | $620,722 |
| Rangeley Capital, LLC | 1.2% | 85,926 | 0.47% | $540,475 | |
| Aldebaran Capital, LLC | 1.1% | 80,630 | 0.45% | $507,163 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 68,167 | +4.1% | 0% | $428,860 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.71% | 52,929 | 0.02% | $332,923 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.69% | 51,638 | +26% | 0.01% | $324,803 |
| FNY Investment Advisers, LLC | 0.67% | 50,000 | 0.09% | $314,000 | |
| Vazirani Asset Management LLC | 0.65% | 48,428 | 1.8% | $304,612 | |
| Shay Capital LLC | 0.45% | 33,699 | -50% | 0.03% | $211,967 |
| RBF Capital, LLC | 0.38% | 28,144 | -0.39% | 0.01% | $177,026 |
| STATE STREET CORP | 0.36% | 27,093 | +28% | 0% | $170,415 |
| DIMENSIONAL FUND ADVISORS LP | 0.36% | 26,543 | +14% | 0% | $166,955 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 0.34% | 25,000 | 0% | 0.13% | $157,250 |
Institutional Holders of Kezar Life Sciences, Inc. - Common Stock (KZR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,345,228 | $9,966,057 | +$109,402 | $7.42 | 9 |
| 2025 Q4 | 4,460,455 | $28,054,562 | +$2,498,477 | $6.29 | 43 |
| 2025 Q3 | 4,206,014 | $16,401,762 | -$1,447,302 | $3.90 | 38 |
| 2025 Q2 | 4,474,800 | $20,493,118 | +$639,707 | $4.58 | 38 |
| 2025 Q1 | 4,328,239 | $21,120,201 | +$284,256 | $4.88 | 40 |
| 2024 Q4 | 4,201,005 | $28,227,155 | +$18,320,837 | $6.72 | 42 |
| 2024 Q3 | 1,440,173 | $1,113,903 | +$1,099,753 | $0.77 | 3 |
| 2024 Q2 | 18,300 | $10,980 | +$10,980 | $0.60 | 1 |